No Data
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $30
Mediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market Potential
MediWound Ltd.'s (NASDAQ:MDWD) Top Owners Are Retail Investors With 38% Stake, While 28% Is Held by Institutions
MediWound Receives Pediatric Indication for Burn Treatment NexoBrid
MediWound and Vericel Win FDA Paediatric Label Expansion for NexoBrid
MediWound Gets FDA Approval for Severe Thermal Burn Treatment for Pediatric Patients